Evaluation of the WHO criteria for the classification of patients with mastocytosis

Modern Pathology

Volumn 24, Issue 9, 2011, Pages 1157-1168

  Sánchez Mũoz, Laura ^a   Alvarez Twose, Ivan ^a   García Montero, Andrés C ^b   Teodosio, Cristina ^b   Jara Acevedo, María ^b   Pedreira, Carlos E ^c   Matito, Almudena ^a   Morgado, Jose Mario T ^a   Sánchez, Maria Luz ^b   Mollejo, Manuela ^a   Gonzalez De Olano, David ^d   Orfao, Alberto ^b   Escribano, Luis ^a  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

Author keywords

Diagnosis; mastocytosis; WHO classification

Indexed keywords

ADOLESCENT; ADULT; AGED; ALGORITHM; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASTOCYTOSIS; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; URTICARIA PIGMENTOSA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; ALGORITHMS; CHILD; FEMALE; HUMANS; MALE; MASTOCYTOSIS; MIDDLE AGED; WORLD HEALTH ORGANIZATION; YOUNG ADULT;

EID: 80052422183     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.84     Document Type: Article

References (39)

1. Metcalfe DD. Clinical advances in mastocytosis: an interdisciplinary roundtable discussion. J Invest Dermatol 1991;96(Suppl):1S-65S.
2. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-625. (Pubitemid 32506768)
3. Valent P, Horny HP, Li CY, et al. Mastocytosis (mast cell disease). In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization (WHO) Classification of Tumours. Pathology & Genetics. Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 291-302.
4. Horny HP, Metcalfe DD, Bennet JM, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC: Lyon, 2008, pp 54-63.
5. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22: 1132-1140. (Pubitemid 28411072)
6. Sperr W, Escribano L, Jordan JH, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001;25:529-536. (Pubitemid 32506759)
7. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001;98:2200-2209.
8. Sperr WR, Jordan JH, Fiegl M, et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002;128:136-141. (Pubitemid 34639022)
9. Sperr WR, Stehberger B, Wimazal F, et al. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002;43:1097-1105. (Pubitemid 34464071)
10. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-4666. (Pubitemid 36857718)
11. Escribano L, Diaz-Agustin B, López A, et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish network on mastocytosis (REMA). Cytometry 2004; 58B:1-8. (Pubitemid 38332714)
12. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-453. (Pubitemid 46817344)
13. Akin C, Fumo G, Yavuz AS, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004;103: 3222-3225. (Pubitemid 38451702)
14. Akin C, Escribano L, Núñ ez R, et al. Well-differentiated systemic mastocytosis: a new disease variant with mature mast cell phenotype and lack of codon c-kit mutations [abstract]. J Allergy Clin Immunol 2004;113:S327.
15. Sonneck K, Florian S, Mullauer L, et al. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2006;142:158-164.
16. Alvarez-Twose I, Gonzalez de OD, Sanchez-Munoz L, et al. Clinical, biological and molecular characteristics of mast cell activation disorders: a prospective study in 62 patients by the Spanish network on mastocytosis (REMA) [abstract]. J Allergy Clin Immunol 2009; 123:S141.
17. Bonadonna P, Perbellini O, Passalacqua G, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680-686.
18. Escribano L, Avarez-Twose I, Sanchez-Munoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-521.
19. Johnson MR, Verstovsek S, Jorgensen JL, et al. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol 2009;22:50-57.
20. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368-381.
21. Miller PD. Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord 2006;7:75-89. (Pubitemid 46044350)
22. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001;25: 543-551. (Pubitemid 32506761)
23. Li CY. Diagnosis of mastocytosis: value of cytochemistry and immunohistochemistry. Leuk Res 2001;25: 537-541.
24. Orfao A, Escribano L, Villarrubia J, et al. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996;149:1493-1499. (Pubitemid 26363956)
25. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998;91:2731-2736. (Pubitemid 28227522)
26. Sotlar K, Fridrich C, Mall A, et al. Detection of c-kit point mutation Asp-816-Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002;26: 979-984. (Pubitemid 35287206)
27. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders. A prospective study of the Spanish network on mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-2372. (Pubitemid 44497521)
28. Escribano L, Orfao A, Villarrubia J, et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 1997;30:98-102. (Pubitemid 27240014)
29. Escribano L, Navalón R, Núñ ez R, et al. Flow cytometry immunophenotypic analysis of human mast cells. In: Robinson JP, Darzynkiewicz Z, Dean P, Orfao A, Rabinovitch P, Wheeless L (eds). Current Protocols in Cytometry. John Wiley & Sons: New York, 2000, pp 661-6618.
30. Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using PNA-mediated PCR-clamping and hybridization probes. Am J Pathol 2003;162:737-746. (Pubitemid 36237482)
31. Wu Y, Basir Z, Kajdacsy-Balla A, et al. Resolution of clonal origins for endometriotic lesions using laser capture microdissection and the human androgen receptor (HUMARA) assay. Fertil Steril 2003;79 (Suppl 1):710-717. (Pubitemid 36279674)
32. Horny HP, Sotlar K, Stellmacher F, et al. The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol 2006;59:298-302. (Pubitemid 43344893)
33. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010;125: 719-726.
34. Valent P, Escribano L, Parwaresch RM, et al. Recent advances in mastocytosis research-summary of the Vienna Mastocytosis Meeting 1998. Int Arch Allergy Immunol 1999;120:1-7. (Pubitemid 29445994)
35. Bodni RA, Sapia S, Galeano A, et al. Indolent systemic mast cell disease: immunophenotypic characterization of bone marrow mast cells by flow cytometry. J Eur Acad Dermatol Venereol 2003;17:160-166. (Pubitemid 36416781)
36. Pardanani A, Kimlinger T, Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004;28:777-783. (Pubitemid 38760039)
37. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells-a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-1325. (Pubitemid 39336370)
38. Bohm A, Fodinger M, Wimazal F, et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 2007;120:192-199. (Pubitemid 46990487)
39. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113: 5727-5736.